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Abstract 
Introduction: Cyclin D1 (D1) binds to cyclin-d e p e n d e n t   k i n a s e s   ( C D K )   4   o r   6   t o   f o r m   a  
holoenzyme that phosphorylates the Rb protein to promote cell cycle progression from G1 
to S phase. Therefore, targeting CDK4/6 may be a good strategy for chemotherapy of cancer. 
W e   p erformed a proof-of-principle study to determine the effect of Naphtho [2, 1-α] pyrrolo 
[3, 4-c] carbazole-5, 7 (6H, 12H)-dione (NPCD) ,   a   n o v e l   C D K 4   i n h i b i t o r ,   o n   b r e a s t   c a n c e r  
cell lines.  
Methods: NPCD was synthesized and purified to over 99% purity verified by HPLC. MCF7, 
M B 2 3 1 ,   M C F 1 5 ,   T 4 7 D   a n d   G I 1 0 1 A p   h u m a n   b r e a s t   c a n c e r   c e l l s   w e r e   a n a l y z e d   f o r   t h e   e f f i c a c y  
o f   N P C D   w i t h   M T T   a n d   c l o n o g e n i c   a s s a y s ,   w i t h   F A C S   a n d   s t a i n i n g   f o r   e t h i d i u m   br o m i d e   a n d  
acridine orange for cell death and cell cycle profile. Western blot, reverse transcription and 
P C R   w e r e   u s e d   f o r   s t u d i e s   o f   g e n e   e x p r e s s i o n ,   a n d   c o -immunoprecipitation  for  pro-
tein-complex formation. 
Results: M T T   a s s a y   s h o w e d   t h a t   N P C D   c a u s e d   g r o w t h   a r r e s t   a n d   a p o p t o s i s   o f   M C F 7 ,  
MDA-MB231, T47D, MCF15 and GI101Ap cells with an IC50 ranging between 3 to 8 µM given 
as a single dose. The growth arrest persisted for many days after cessation of the treatment, 
as shown in a clonogenic assay. NPCD could induce or reduce the D1 and CDK4 protein 
levels, depending on the cell line, but this effect was not correlated with its efficacy. Phos-
phorylation of D1 at Thr286 was decreased but it unexpectedly did not correlate with the 
change in D1 level in the cell lines studied. Phosphorylation of the Rb protein was decreased 
as expected whereas the p27kip1 protein level was decreased unexpectedly. Protein levels of 
p21cip1, CDK2 and cyclin E were also decreased in some, but not all, of the cell lines, whereas 
the mRNA levels of D1, CDK4, cyclin E, CDK2, p27kip1 and p21cip1 were increased in 
different cell lines.  
Conclusions: N P C D   c a n   c a u s e   l o n g -l a s t i n g   g r o w t h   a r r e s t   a n d   c e l l   d e a t h   o f   b r e a s t   c a n c e r   c e l l  
lines at an IC50 of 3-8 µM. Decreased phosphorylation of Rb by D1-CDK4/6 and decreased 
p27kip1 protein level may be part of the underlying mechanism. 
Key words: NPCD , CDK4 Inhibitor, breast cancer cell lines 
Introduction 
D-type  cyclins,  including  D1,  D2  and  D3,  are 
u s u a l l y   i n d u c e d   b y   m a n y   g r o w t h   f a c t o r s   a n d   o n c o-
proteins such as Ras, epidermal growth factor (EGF), 
etc [1].   D -t y p e   c y c l i n s   r e l a y   t h e  extracellular mitogenic 
signals of these factors to the cell cycle machinery and 
d r i v e   c e l l   c y c l e   p r o g r e s s i o n   f r o m   G 1   t o   S  phase  [2]. Journal of Cancer 2011, 2 
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O n c e   t h e   c e l l s   p a s s   t h e   l a t e   s t a g e   o f   G 1   p h a s e   a n d   are 
a b o u t   t o   e n t e r   S   p h a s e ,   t h e   c e l l s   c a n   c o m p l e t e the cell 
cycle without any need for further stimulus, although 
additional stimuli may still further accelerate comple-
t i o n   o f   t h e   o n g o i n g   c e l l   c y c l e .   F o r   t h i s   r e a s o n ,   D -type 
cyclins, mainly D1, are regarded as mitogenic sensors 
of  cells.  This  unique  trait  constitutes  an  important 
foundation for targeting D1 for cancer therapy. 
D1 is amplified in about 15% of breast cancer 
cases in general, b u t   i n   a b o u t   2 1 %   o f   t h e   e s t r o g e n   r e-
ceptor alpha positive cases [3]. D1 amplification also 
occurs at high frequencies in lymphomas [4] and other 
malignanc i e s ,   a s   r e v i e w e d   b y   u s  [1]. It goes without 
saying  that D1 overexpression occurs at even higher 
frequencies in cancers, close to 50% in breast cancer as 
reported in some studies [5]. D1 overexpression also 
distinguishes invasive and in situ breast carcinomas 
from non-malignant lesions [6]. Besides these altera-
t i o n s   s h a r e d   b y   o t h e r   m a l i g n a n c i e s ,   D 1   i s   e x c e p t i o n-
a l l y   i m p o r t a n t   f o r   t h e   m a m m a r y   g l a n d   a n d   b r e a s t  
cancer f o r   t w o   s p e c i f i c   r e a s o n s :   1 )   i t   i s   t h e   o n l y   D   t y p e  
cyclin expressed in the mammary gland and controls 
mammary  gland  development  [7];  2)  it  is  a  major 
downstream effector of estrogen receptors [8].  
D1  associates  with  cyclin-dependent-kinase 
CDK4  or  CDK6  to  form  an  active  holoenzyme  to 
phosphorylate and thus inactivate Rb. Inactivated Rb 
releases E2F proteins to exert transcriptional activities 
o f   g e n e s   r e l a t e d   t o   c e l l   c y c l e   p r o g r e s s i o n .   A l t h o u g h   D 1  
a l s o   h a s   o t h e r   f u n c t i o n s   i n d e p e n d e n t   o f   C D K 4   o r  
CDK6, its activation of CDK4/6 is still considered the 
major  mechanism  for  D1’s  oncogenic  functions. 
Therefore, it is conceivable that inhibition of CDK4/6 
k i n a s e   a c t i v i t y   t o w a r d   t h e   R b   p r o t e i n   s h o u l d   b l o c k   t h e  
D1’s  oncogenic  functions.  Based  on  this  rationale, 
many investigators consider targeting D 1   o r   i t s   p a r t-
n e r   C D K s   a s   a   s t r a t e g y  for  cancer  treatment  [9-16]. 
Chemical  inhibitors  of  D1  [17-25]  or  CDK4  [26-36] 
have been developed as  candidates for chemothera-
peutic  agents  [26,37-43].  Of  the  CDK4  inhibitors, 
PD0332991 developed by Pfizer Global Research and 
Development  as  a  pyridopyrimidine  derivative 
[41,44] shows promising efficacy on several  types  of 
c a n c e r   a n d   h a s   a l r e a d y   e n t e r e d   c l i n i c a l   t r i a l s   [45,46]. A 
recent study shows that PD0332991 has good efficacy 
o n   a   p a n e l   o f   4 4   h u m a n   b r e a s t   c a n c e r   c e l l   l i n e s ,   w i t h   a  
higher  sensitivity  on  those  cells  expressing  higher 
levels o f   p R b   o r   D 1   p r o t e i n s   o r   l o w e r   l e v e l s   o f   t h e   p 1 6  
cdk4/6 inhibitor [47].  
Several indolocarbazole analogs have also been 
developed  as  very  potent  CDK4  inhibitors 
[29-31,33,35,36,39,40].  For  instance,  naphyl[a]pyrolo 
[3,4-c]carbazole-5,7(6H,  12,H)-dione  (NPCD)  and 
isoquinolinyl[a]pyrrolo[34-c]carbazole  (IQPC)  have 
an IC50 on  CDK4 at a range of 45-75 nM while affect-
i n g   o t h e r   C D K s ,   s u c h   a s   C D K 2 , at much higher con-
centrations  [31,35].  However,  the  efficacy  of  these 
indolocarbazole a n a l o g s   o n   c a n c e r s   i s  unknown so far. 
Moreover, little is known about the molecular  path-
ways triggered by CDK4 inhibitors in general and by 
indolocarbazole-derivatives  in  particular.  The  indo-
locarbazoles are  shown  to  be  selective  G1  blockers 
while  their  bis-indolylmaleimide  precursors  arrest 
cells  in  the  G2/M  phase [31,48]. O n e   o f   t h e s e   c o m-
pounds,  2-bromo-12,13-dihydro-indolo[2,3-a]pyrrolo 
[3,4-c]carbazole-5,7(6H)-dione  (219476  from  Calbio-
chem),   h a s   b e e n   s h o w n   t o   b e   a b l e   t o   d e g r a d e   I κ B   a n d  
induce  translocation  of  RelA  from  the  cytoplasm  to 
the nucleoplasm and then to the nucleolus, leading to 
suppression  of  NF-κB activity as a collective result 
[49,50].  
In the present study, we determine the in vitro 
effect of NPCD in human breast cancer cell lines as a 
proof-of-principle study for targeting D1-CDK4 as a 
strategy for cancer therapy. We observe  that  NPCD 
arrests cells at G1 phase and causes apoptosis with an 
IC50 of 3-8 µM when administered as  a  single  dose. 
These  effects  are  surprisingly  long-lasting  as  deter-
mined by a clonogenic survival assay and are asso-
ciated with an unexpected decrease in p27kip1 and 
p21cip1 proteins. Phosphorylation of the Rb protein is 
decreased as expected, whereas D1 and CDK4 protein 
levels are reduced in some cell lines but induced in 
others,   w h i c h   h a s   n o t   b e e n   r e p o r t e d   f o r   o t h e r   C D K 4  
inhibitory  compounds  such  as  PD0332991.  To  our 
knowledge this study is the first comprehensive one 
on  NPCD in a panel of breast cancer cell lines that 
h a v e   d i f f e r e n t   f e a t u r e s   o f   t u m o r   b i o l o g y   a n d   t h u s   t h e  
data presented herein are novel. 
Materials and Methods 
Cell lines: M C F 1 5   i s   a   n e w   h u m a n breast cancer 
cell  line  [51].  GI101Ap  is  a  clone  of  GI101A  cells 
kindly provided by D r .   J a n e t   E .   P r i c e   a t   t h e   M D   A n-
derson Cancer Center, the U n i v e r s i t y   o f   T e x a s ,   H o u-
s t o n .   M C F 1 0 A   c e l l s   w e r e   o b t a i n e d   f r o m   K a r m a n o s  
Cancer Center (Detroit, Michigan), which is the for-
mer Michigan Cancer Foundation that developed the 
MCF  series  of  cells,  whereas  MCF7,  T47D  and 
MDA-MB231 (MB231) human breast cancer cell lines 
were  originally  obtained  from  the  American  Type 
C u l t u r e   C o l l e c t i o n   ( A T C C ) .   A m o n g   t h e s e   c e l l   l i n e s ,  
MCF7, MCF15 and T47D cells are estrogen receptor 
(ER) α   n e g a t i v e   i n   c u l t u r e , T47D and MB231 cells have 
p53 mutations, w h e r e a s   t h e   E R α   n e g a t i v e   M B 2 3 1   a n d  
ERα positive GI101Ap are two most commonly used 
metastatic  cell  lines,  after  MDA-MB435  is  recently 
c h a r a c t e r i z e d   t o   b e   o f   m e l a n o m a   o r i g i n   [52]. Moreo-Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
38 
v e r ,   M B 2 3 1   c e l l s   a r e   s o -called triple-negative  (estro-
gen receptor, progesterone receptor and Her-2 nega-
tive). 
Reagents: Naphtho [2, 1-α] pyrrolo [3, 4-c]  car-
bazole-5, 7 (6H, 12H)-dione  (NPCD) (fig 1) was syn-
t h e s i z e d   a n d   p u r i f i e d   b y   u s   a t   a   purity of over 99% 
proved  by  HPLC.  It  was  dissolved  with  dimethyl 
sulfoxide ( D M S O )   a n d   k e p t   a t   -20oC until use. Unless 
specified separately, primary antibodies used in this 
study w e r e   p u r c h a s e d   f r o m   S a n t a   C r u z   B i o t e c h n o l o g y  
Inc  (Santa  Cruz,  CA),  including  mouse  monoclonal 
anti-β-actin  (sc-47778)  as  well  as  rabbit  polyclonal 
anti-cyclin D1 (sc-718), anti-CDK4 (sc-260), anti-CDK6 
(sc-7180),  anti-CDK2  (sc-163),  anti-cyclin  E  (sc-481), 
anti-Rb  (sc-50), anti-pRb  (Ser807/811;  sc-16670),  an-
ti-p27  (sc-528),  and  anti-p21  (sc-397).  The  anti-pRb 
Ser780  (Cat#9307)  rabbit  polyclonal  antibody  was 
purchased  from  Cell  Signaling  Technology,  Inc 
(Danvers,  MA).  Peroxidase-conjugated  anti-mouse 
(NA931) and  anti-rabbit (NA934) secondary antibo-
d i e s   w e r e   p u r c h a s e d   f r o m   A m e r s h a m   B i osciences 
(Piscataway, NJ). 
 
 
Fig 1: Chemical structure of Naphtho [2, 1-α] pyrrolo [3, 
4-c] carbazole-5, 7 (6H, 12H)-dione (NPCD). 
 
 
3-(4,  5-Dimethylthiazol-2-yl)-2,  5-diphenylte-
trazolium bromide (MTT) assay: Cells were seeded 
in  a  96-well micro-p l a t e   a t   4 , 0 0 0   c e l l s   p e r   w e l l ,  five 
w e l l s   p e r   d o s e   a n d   p e r   t i m e   p o i n t ,   and incubated at 
37oC with 5% CO2. NPCD was added 24 hours later at 
indicated concentrations, with DMSO as non-treated 
control. The culture was continued for the indicated 
time period. A t   t h e   e n d   o f   the treatment,  MTT  was 
added  into  each  well  at  a  final  concentration  of 
0.5mg/ml followed by incubation at 37oC  for  three 
hours in d a r k .   T h e   c u l t u r e   m e d i u m   c ontaining MTT 
was discarded and the dye crystals were dissolved in 
D M S O .   T h e   v i a b l e   c e l l s   w e r e   d e t e c t e d   b y   r e a d i n g   t h e  
absorbance  of  the  metabolic  MTT  at  wavelength 
570nm using the Beckman Coulter AD340 absorbance 
detector  (Beckman  Coulter  Inc,  Fullerton,  CA).  The 
experiment was repeated at least three times t o   e n s u r e  
the data reproducibility. 
Clonogenic survival assay: Cells were seeded in 
24-well  culture  plates at 1x105 c e l l s   p e r   w e l l   a n d   2 4  
hours  later NPCD was added into the culture, with 
DMSO  as  non-treated c o n t r o l .   T h e   c e l l s   w e r e   t r y p s i-
n i z e d   7 2   h o u r s   a f t e r   t h e   N P C D   t r e a t m e n t   and evenly 
reseeded at a lower density (1x103 cells per well) in 
triplicate in a 6-well culture plate. Cells were main-
tained  in  culture  for  10  to  15  days,  with  medium 
change e v e r y   3   d a y s ,   t o   l e t   t h e   v i a b l e   c e l l s   p r o p a g a t e  
to  sizable  colonies  for  quantification.  The  colonies 
were fixed with methanol-acetic acid at 3:1 ratio and 
then stained with 1% crystal violet for 30 minutes at 
r o o m   t e m p e r a t u r e .   T h e   n u m b e r   o f   c o l o n ies formed in 
each well was counted and photographed under the 
microscope. The experiment was repeated three times 
and  the  resulting  data  are  presented  after  statistical 
processing. 
Acridine orange and ethidium bromide stain-
ing: Cells were seeded in 96-well plates at 3,000 cells 
per well and incubated at 37 oC   w i t h   5 %   C O 2. NPCD at 
a final concentration o f   2   o r   4  µM was added 24 hours 
later in multiple repetitions (5 wells per dose); plates 
were incubated for an additional 24 or 48 hours. Prior 
to cell staining, the medium was discarded.  The cells 
were  washed  with  phosphate-buffered  saline  (PBS) 
f i r s t   a n d   t h e n   i n c u b a t e d   w i t h   1 0  µl PBS containing 10 
µg/ml  of  Ethidium  Bromide  (EB)  and  3  µg/ml  of 
A c r i d i n e   o r a n g e   ( A O ) .   T h e   c e l l s   s t a i n e d   b y   E B   a n d   A O  
were immediately visualized under the Le i c a   D M   I R B  
inverted  fluorescence  microscope  (Leica  Microsys-
tems  Inc.  Bannockburn,  IL).  Multiple  photos  were 
taken at randomly-selected areas of the well to ensure 
that  the  data  obtained  are  representative.  Photo-
graphs  were  processed  using  “Image  ProPlus  6.0” 
ultimate image analysis software (Media Cybernetics, 
Inc. Bethesda, MD). 
Cell cycle analysis: Cells were cultured in 6-cm 
culture dishes until they reached 70~80% confluence. 
NPCD was given at an indicated concentration with 
DMSO  as  non-treated  control;  the  cells  were  har-
v e s t e d   3 6   o r   4 8   h o u r s   l a t e r .   A t   t h e   c e s s a t i o n   o f   t h e  
treatment, both floating and adherent cells were col-
l e c t e d ,   c o m b i n e d ,   w a s h e d   w i t h   c o l d   P B S ,   a n d   t h e n  
fixed overnight with 70% ethanol in PBS at -20oC. The 
cells were then washed with PBS again and incubated 
in the dark with in a PBS solution containing 20µg/ml 
propidium  iodide  (PI)  and  200µg/ml  RNase  for  30 
minutes  at room temperature. The cells  at  different 
s t a g e s   o f   t h e   c e l l   c y c l e   w e r e  detected  with a  Becton 
Dickinson  FACS  Calibur  flow  cytometer  (BD  Bios-
ciences, San Jose, CA). I n t a c t   c e l l s   w e r e   g a t e d   i n   t h e  
FSC/SSC plot to exclude small debris. The population Journal of Cancer 2011, 2 
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of cells   a t   d i f f e r e n t   s t a g e s o f   t h e   c e l l   c y c l e   w a s   q u a n t i-
fied  u s i n g   M o d F i t   L T   s o f t w a r e   ( V e r i t y   S o f t w a r e  
House, Inc., Topsham, ME).  
Cell  death  analysis:  Annexin  V  and  PI  dual 
staining was used to visualize apoptotic and necrotic 
cells in a similar procedure as described above but the 
cells were not pre-fixed with 70% ethanol. Apoptotic 
cells were stained using the Annexin V-FITC Apop-
tosis  Detection  Kit  (MBL  International  Corporation, 
Watertown,  MA)  following  the  manufacturer’s  in-
s t r u c t i o n .   A l l   d e a d   c e l l s ,   i . e .   b o t h   a p o p t o t i c   a n d   n e-
c r o t i c   c e l l s   s t a i n e d   b y   A n n e x i n   V   a n d PI, were ana-
lyzed  by a Becton Dickinson FACS-Calibur flow cy-
tometer (BD Biosciences, San Jose, CA), which places 
the Annexin V-FITC signal that detects apoptosis in 
F L 1   a n d   t h e   P I -FITC  signal  that  detects  necrosis  in 
FL2. Therefore, cells in the upper-left quadrant of the 
FL1/FL2  dot  plot  (labeled  with  PI-FITC  only)  as 
s h o w n   i n   f i g u r e   3   w e r e   n e c r o t i c ,   w h e r e a s   c e l l s   i n   t h e  
bottom-right quadrant were early apoptotic. Cells in 
the  upper-right  quadrant  (labeled  with  Annexin 
V-FITC and PI) were late apoptotic or necrotic. 
Protein extraction and western  blotting  assay: 
T o t a l   p r o t e i n   s a m p l e s   o r   n u c l e a r   a n d   c y t o p l a s m i c  
proteins were extracted as described by Andrew and 
Faller [53], followed by determination of protein con-
centration using a Bradford assay (Bio-Rad Laborato-
r i e s   I n c .   H e r c u l e s ,   C A ) .   An  equal amount of protein 
f r o m   e a c h   s a m p l e   w a s   f r a c t i o n e d   i n   S D S -PAGE and 
then  transferred  onto  an Immobilon-P   N y l o n   m e m-
b r a n e   ( M i l l i p o r e ,   B e d f o r d ,   M A )   i n   a   t a n k   t r a n s f e r 
system. After being blocked with 5 %   m i l k ,   t h e   m e m-
brane was incubated with specific primary antibody 
at an optimized concentration and then with horsera-
dish peroxidase-conjugated secondary antibody, with 
three washes between each antibody.   T h e   s i g n a l  was 
visualized  with  ECL  chemiluminescent  substrates 
(Pierce, Rockford, IL) on X-ray film (ISC BioExpress, 
Kaysville, UT). The expression levels were quantified 
a s   t h e   b a n d   d e n s i t y   o n   X -film using ImageJ software, 
calculated as the ratio to the  β-actin expressed in the 
same sample, and presented as number of “+”. +++, 
++  and  +  indicate that  the  ratio  to  β-actin is larger 
than 0.75, between 0.5~0.75, and less then 0.5, respec-
t i v e l y ,   w h e r e a s   ±   a n d   ( -)   i n d i c a t e   a   v e r y   l o w   l e v e l   o f  
expression and the absence of the signal on the X-film, 
respectively. T h e   R b   p r o t e i n   w a s   u s e d   a s   a   l o a d i n g  
control  for  nuclear  proteins  in some of the western 
blot assays as reported in the literature [54,55]. 
Co-immunoprecipitation  assay:  D1-CDK4 
complex  formation  was  analyzed  with 
co-immunoprecipitation  assay. Total protein lysates 
(500µg) from each sample were immunoprecipitated 
( I P )   i n   4 0 0 µ l   l y s a t e   b u f f e r   c o n t a i n i n g   2 µ l  anti-c y c l i n   D 1  
(sc-718) or anti-CDK4 (sc-260) rabbit polyclonal anti-
body and inhibitors of various proteases,  phospho-
tases  and kinases at 4oC   f o r   4   hours  with  rotation. 
Protein A-conjugated agarose beads (25 µl) were then 
added into the IP reaction with an additional 5 hours 
of  rotation  at  4oC.  The  antigen-antibody complexes 
were precipitated by a quick centrifugation, followed 
b y   f o u r   t i m e s   o f   w a s h   w i t h  cold PBS. Proper controls 
i n c l u d e d   a n   a l i q u o t   o f   r a b b i t   s e r u m   t o   r e p l a c e   t h e   D 1  
or CDK4   a n t i b o d y   i n   t h e   I P   r e a c t i o n .   T h e   p e l l e t s   w e r e  
suspended  in  20µl  2xSDS  reducing  western  blot 
loading buffer and boiled for 5 minutes, followed by 
SDS-PAGE.  The  D1-  or  CDK4-immunoprecipitates 
were subjected to western blot assay to detect the D1 
or CDK4 in the immunoprecipitates. 
RT-PCR  assay:  T o t a l   R N A   s a m p l e s   w e r e   e x-
tracted from cultured cells using TRIzol (Invitrogen, 
Cat.  15596-026) in a routine procedure, followed by 
DNaseI treatment t o   g e t   r i d   o f   D N A   r e s i d u a l .   An ali-
q u o t   ( 2 . 5 µ g )   o f   t h e   R N A   s a m p l e s   w a s   t h e n   r e v e r s e  
transcribed (RT) in a 25µl reaction solution to the first 
s t r a n d   o f   c D N A   u s i n g   h e x a m e r   p r i m e r .   T h e   R T  
p r o d u c t s   w e r e   d i l u t e d   w i t h   w a t e r   t o   t h e   f i n a l   v o l u m e  
of 50 µl. For PCR amplification of each target gene, 1 
µ l   o f   t h e   d i l u t e d   R T   p r o d u c t s   w a s   u s e d   a s   t e m p l a t e ,  
but the template was further diluted 10 times for PCR 
amplification of β-a c t i n   s o   a s   t o   c o n t r o l   t h e   P C R   a m-
plification of this highly expressed gene at the linear 
portion. The PCR condition (table 1) was optimized 
f o r   e a c h   g e n e   a n d   w a s   s t o p p e d   w i t h i n   t h e   l i n e a r   p o r-
tion  of  the  amplification.  The  forward  and  reverse 
p r i m e r s   f o r   e a c h   g e n e ,   l i s t e d   i n   t a b l e   1 ,  were designed 
i n   s u c h   a   w a y   t h a t   t h e y   a r e   l o c a l i z e d   a t   t w o   d i f f e r e n t  
exons of the given gene with one or several large in-
trons in between. In this way if there still is a traceable 
a m o u n t   o f   D N A   r e s i dual, it either cannot be amplified 
due to large intron(s) or is amplified as a molecule 
larger than the expected size indicated in table 1. PCR 
products were separated and visualized in 1% agarose 
gel. 
Statistic  analyses:  A l l   M T T ,   F A C S   a n d   c l o n o-
genic  survival  assays  were  performed  in  multiple 
repetitions in each experiment, and the experiments 
were  repeated  at  least  three  times.  The  data  were 
p r e s e n t e d   a s   m e a n   ±   S E .   S t a t i s t i c a l   c o m p a r i s o n s   b e-
t w e e n   g r o u p s   w e r e   m a d e   w i t h   t h e   s t u d e n t ’ s   t -test. A P 
value < 0.05 is considered as significant.  
Results 
Effect of NPCD on cell survival 
MCF7, MB231, MCF15, T47D and GI101Ap cells 
were  treated  once  with  NPCD  at  escalating concen-
trations (1-10 μM), and the number of viable cells was Journal of Cancer 2011, 2 
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determined with an MTT assay 48 or 72 hours  later. 
The results showed t h a t   M C F 7   a n d   M C F 1 5   c e l l s   w e r e  
the most sensitive to NPCD-induced decrease in cell 
viability whereas  GI101Ap and T47D cells were  less 
sensitive. The sensitivity of   M B 2 3 1   c e l l s   t o   N P C D   w a s  
intermediate. Nevertheless, the IC50s for all five can-
c e r   c e l l   l i n e s   7 2   h o u r s   a f t e r   a   s i n g l e   a d ministration 
were  close,  ranging  between  3-8  µM  (table  2).  The 
response of MCF10A non-transformed human breast 
epithelial cells was slightly less sensitive than most of 
these cancer cells, with IC50 between 8-10 µM (table 
2). 
 
 
Table 1: Primer sequences and PCR amplification conditions used in RT-PCR assay. 
 
 
 
Table 2: IC50 of NPCD on five breast cancer cell lines and MCF10A non-transformed cells  
 
 
 
A decrease in the number of viable cells detected 
b y   M T T   m a y   b e   a t t r i b u t a b l e   t o   d e c r e a s e d   c e l l   p r o l i f e-
r a t i o n ,   i n c r e a s e d   c e l l   d e a t h ,   o r   b o t h .   T o   d e t e r m i n e  
w h i c h   o f   t h e s e   t w o   e l e m e n t s   i s   t h e   m a i n   m e c h a n i s m ,  
MCF7,  MB231  and  MCF15, the three more sensitive 
c e l l   l i n e s ,   w e r e   t r e a t e d   w i t h   4   μ M   o f   N P C D   a n d   t h e n  
s u b j e c t e d   t o   a   c l o n o g e n i c   s u r v i v a l   a s s a y .   T h e   n u m b e r  
of colonies developed 10-1 5   d a y s   a f t e r   N P C D   t r e a t-
ment was quantified and calculated as a percentage of 
the corresponding non-treated control. This was used 
as  the  survival rate, which was 7.48±1% for MCF7, 
23.59±0.2% for MB231, and 38.00±6% for MCF15 cells, 
r e s p e c t i v e l y   ( f i g   2 ) .   T h e   p h o t o s   o f   c o l o n i e s   o f   t r e a t e d  
or non-treated cells from a representative experiment 
are also show n   i n   f i g u r e   2 .   I n t e r e s t i n g l y ,   n o t   o n l y   t h e  
number,  b u t   a l s o   t h e   s i z e ,  of  the  colonies  in 
NPCD-treated  groups  was  decreased,  especially  in 
MCF7 cells. Because some colonies in treated groups 
were too small to appear in the macroscopic photos 
shown in figure   2   b u t  could be quantified under the 
microscope,  the  difference  in  quantitative  data  be-
tween the treated and non-treated groups seemed to 
b e   s m a l l e r   t h a n   w h a t   w a s   r e f l e c t e d   b y   t h e   p h o t o s ,  
especially in MCF7 cells. Because the clonogenic assay 
was  terminated  10-1 5   d a y s   a f t e r   c e s s a t i o n   o f   t h e  
t r e a t m e n t   a n d   b e c a u s e   a   s m a l l e r   c o l o n y   s i z e   i n d i c a t e s  
fewer cells propagated from a single survival cell in a 
given time period, this result indicates a persistent or 
long-lasting growth arrest caused by NPCD. Journal of Cancer 2011, 2 
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Fig 2: Results of colony survival assay. Colonies developed from MCF7, MB231 or MCF15 cells 10-15 days after being 
treated with 4µM NPCD, or untreated, in a representative experiment were shown, with each cell line in thre e   w e l l s   o f   t h e  
6-well culture plate. Quantitative data from three different experiments were presented in the histogram. 
 
Effects of NPCD on cell cycle and apoptotic pro-
files 
Analysis of cell cycle profile with FACS revealed 
that NPCD treatment of MCF7, MB231 and MCF15 
cells at relatively low concentrations (2-4 μM) for 36 
h o u r s   s i g n i f i c a n t l y   a r r e s t e d   t h e   c e l l s   a t   G 1   p h a s e ,   a s  
evidenced by an increased percentage of the cells at 
G1 phase and a corresponding decrease in the per-
ce n t a g e   o f   t h e   c e l l s   a t   S   p h a s e  (table  3).  MCF15  cells 
a l s o   s h o w e d   a   d e c r e a s e   i n   t h e   c e l l s   a t   G 2   p h a s e   ( table 
3).  Apoptotic  cells  at  the  sub-G1  phase  were  also 
slightly  increased  by  these  low  concentrations  of 
NPCD at this early time point.  
Apoptotic  cells  were  visualized  by  acridine 
orange/ethidium bromide staining upon treatment of 
M C F 7   a n d   M B 2 3 1   c e l l s   w i t h   2   o r   4   μ M   N P C D   f o r   4 8  
hours (fig 3A). We also used annexin V/PI staining to 
identify the dead cells and stratified them into  cate-
gories of necrosis, early apoptosis, and both of later 
a p o p t o s i s   a n d   n e c r o s i s .   I n   e a c h   g r a p h   o f   f l o w   c y t o-
m e t r y   ( f i g   3 B -D), necrosis is shown in the upper-left 
guardant,  early  apoptotic  cells  in  the  bottom-right 
q u a d r a n t ,   a n d   l a t e r   a p o p t o t i c   o r   n e c r o t i c   c e l l s   i n   t h e  
upper-right quadrant. The total death rate of all three 
fractions  36  and  48  hours  after  NPCD  treatment 
showed 2- (56.6 vs 27.9%) and 3- (69.7 vs 22.1%) fold 
increase, respectively, for MCF7 cells, and 3- (37.6 vs 
11.1%) and 7-  (88.6 vs 12.5%) fold increase, respec-
tive l y ,   f o r   M B 2 3 1   c e l l s .   I n t e r e s t i n g l y ,   t h e   d e a t h   r a t e   o f  
MCF15  cells  was  not  changed  (15.4  vs  11.3%)  at  36 
h o u r s   b u t   i t   s h o w e d   a   1 0 -fold (75.6 vs 7.5%) increase at 
4 8   h o u r s .   I t   s e e m s   t h a t   t h e   e f f e c t   o c c u r s   s l i g h t l y   l a t e r  
i n   M C F 1 5   c e l l s   s i n c e   M C F 7   a n d   M B 2 3 1   c ells had al-
ready shown an obvious increase in cell death at 36 
h o u r s .   I n   l i n e   w i t h   t h e s e   d a t a ,   w e   o b s e r v e d   m a n y  
floating cells and cell debris in the culture dishes after 
N P C D   t r e a t m e n t ,   w h i c h   c o n f i r m s   t h e   o c c u r r e n c e   o f  
cell death. 
Inhibition of Rb phosphorylation by NPCD 
D1-CDK4  and  D1-CDK6  are  known  to  phos-
phorylate the Rb protein at ser780, ser807 and ser811 
[56,57]. Use of antibodies that specifically recognize 
these phosphorylation  sites in western blot showed 
that the amount of Rb phosphorylated at these sites 
was  indeed  decreased  upon  treatment  of  MCF7, 
MB231 and MCF15 cells with NPCD at 4 or 8   μ M   f o r  
4 8   h o u r s   ( f i g   4 )   a n d   7 2   h o u r s   ( d a t a   n o t   s h o w n ) .   T h e  
total amount of Rb protein was also slightly decreased 
i n   M B 2 3 1   a n d   M C F 1 5   c e l l s   t r e a t e d   w i t h   t h e   h i g h   d o s e  
o f   N P C D   ( f i g   4 ) ,   w h i c h   m a y   i n   p a r t   c o n t r i b u t e   t o   t h e  
decrease in the phosphorylated fraction of the Rb in 
these cells. Journal of Cancer 2011, 2 
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Table 3: Cell cycle profile of breast cancer cells treated with NPCD 
 
 
 
 
 
F i g   3 : NPCD induced death of MCF7, MB231 and MCF15 cells. A): Acridine orange/ethidium bromide staining shows viable 
c e l l s   i n   g r e e n   f l u o r e s c e n c e   a n d   d e a d   c e l l s   i n   r e d -orange fluorescence. B, C and D): Necrotic (upper-left quadrant), early 
apoptotic (bottom-right quadrant) and both late apoptotic and necrotic (upper-right quadrant) fractions of MCF7 (B), 
MB231 (C) and MCF15 (D) cells 36 or 48 hours after treatment with 5 µM NPCD. Journal of Cancer 2011, 2 
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Effects of NPCD on the protein levels of G1 
phase regulators 
B e c a u s e   N P C D   w a s   d e v e l o p e d   a s   a   C D K 4   i n h i-
bitor, we wondered whether its efficacy is affected by 
the levels of D1 and/or CDK4. We thus conducted 
western blot using cell lysates of the five breast cancer 
c e l l   l i n e s   t o   d e t e r m i n e   t h e   p r o t e i n   l e v e l s   o f   D 1 ,   D 2 ,   D 3 ,  
CDK4,  CDK6,  CDK2,  p27kip1  (p27)  and  p16ink4a. 
Western  blot  for  each  protein  was  repeated  several 
times. The protein levels were quantified as the band 
density  on  X-ray-film,  calculated  as  the  ratio  to 
β-actin expressed in the same sample, and  pre-
s e n t e d   a s   n u m b e r   o f   “ + ”   w i t h   m o r e   “ + ”   t o   i n d i c a t e   a  
higher expression level (table 4).   D 2   a n d   D 3   p r o t e i n s  
were  expressed  at  very  low  levels  in  these  cells  as 
expected, whereas p16ink4a was basically undetecta-
ble  in  these  cell  lines  and  thus  not  presented.  The 
p r o t e i n   l e v e l s   o f   D 1 ,   C D K 4   a n d   C D K 6   w e r e   l o w e r   i n 
T47D and GI101Ap cells that were relatively resistant 
t o   N P C D ,   s u g g e s t i n g   a   p o s s i b i l i t y   t h a t   N P C D   m i g h t  
be more effective in the cells that express a relatively 
higher level of these proteins, which is in line with the 
o b s e r v a t i o n   o f   F i n n   e t   a l   t h a t   b r e a st cancer cell lines 
with higher D1 levels are more sensitive to PD032991 
[47]. Considering that the Rb protein is the ultimate 
target   o f   t h e   G 1   r e g u l a t o r y   p r o t e i n s ,   w e   a l s o   d e t e r-
mined the total Rb protein level in the cell lines stu-
d i e d ,   a n d   f o u n d   t h a t   i t   v a r i e d   o n l y   s l i g h t l y   a m o n g   t h e  
cells (table 4). 
T r e a t m e n t   w i t h   4   o r   8   μ M   N P C D   f o r   7 2   h o u r s  
significantly decreased the D1 protein levels in MCF7 
and MCF15 cells (fig 5). In  contrast,  the  D1  protein 
level was significantly increased by the treatment at 
48 and 72 hours in MB231 cells (fig 5).  NPCD  treat-
ment decreased the C D K 4   p r o t e i n   l e v e l   i n   M C F 7   a n d  
MCF15  cells at  both  time points, wher e a s   i t   d i d   n o t  
o b v i o u s l y   a f f e c t   C D K 4   i n   M B 2 3 1   c e l l s   ( f i g   5 ) .   C D K 6  
p r o t e i n   w a s   d e c r e a s e d   i n   M C F 1 5   c e l l s   b u t   d i d   n o t  
show o b v i o u s   c h a n g e   i n   M C F 7   a n d   M B 2 3 1   c e l l s   ( f i g  
5). P27 protein level was dramatically decreased at 48 
h o u r s   i n   a l l   t h r e e   M C F 7 ,   M B 2 3 1   a n d   M CF15 cells. P21 
protein level was decreased in MCF7 and MCF15 cells 
a t   7 2   h o u r s ,   b u t   i t   w a s   n o t   o b v i o u s l y   c h a n g e d   i n  
MB231 cells. 
NPCD  also  inhibited  cyclin  E-CDK2  with  an 
ID50 at 270 nM, which is much higher than the IC50 at 
4 5   n M   f o r   t h e   i n h i b i t i o n   o f   D 1 -CDK4  [30,31,35].  In 
m o s t   o c c a s i o n s   t h e   l e v e l s   o f   c y c l i n   E   a n d   C D K 2   p r o-
teins seemed to be changed in a reciprocal manner in 
response to NPCD treatment, i.e. an increase in cyclin 
E   m i g h t   b e  accompanied b y   a   d e c r e a s e   i n   C D K 2   a n d  
v i c e   v e r s a .   I n   M B 2 31  cells,  CDK2 was decreased at 
both time points whereas cyclin E protein level was 
slightly increased at the high dose group. Although 
CDK2 levels in MCF15 cells were low and were de-
creased  by  NPCD  treatment,  cyclin  E  levels  were 
higher in this cell line, even after NPCD treatment (fig 
5 ) .     H o w e v e r ,   t h e   r e c i p r o c a l   p a t t e r n   w a s   n o t   o b v i o u s  
in MCF7 cells, in which NPCD did not obviously af-
f e c t   C D K 2   w h i l e   i t   c a u s e d   a   s l i g h t   b i -phase change in 
cyclin E, i.e. an initial decrease at 48 hours followed by 
a recovery   t o   n o r m a l   o r   e v e n   a   s l i g h t   i n c r e a s e   a t   7 2  
hours, especially in the low dose group (fig 5).  
 
Table 4.  Relative expression level of several G1 regulatory proteins in five human breast cancer cell lines * 
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Fig 4: Phosphorylation of the Rb protein at ser780 or ser807/ser811 in MCF7, MB231 or MCF15 cells 48 hours after 
treatment with 4 or 8µM NPCD, with β-actin as loading control. 
 
 
Cellular location of D1-CDK4 and cyclin E-CDK2 
and Phosphorylation of D1 at Thr286 
A   m a j o r   m e c h a n i s m   c o n t r o l l i n g   D 1   p r o t e i n   l evel 
is  its  phosphorylation  at  Thr286  by  GSK-3 β   i n   t h e  
n u c l e u s ,   f o l l o w e d   b y   n u c l e a r   e x p o r t   a n d   p r o t e a s o m a l  
degradation  in  the  cytoplasm.  Because  MCF7  and 
M B 2 3 1   c e l l s   s h o w   t h e   o p p o s i t e   c h a n g e   i n   D 1   l e v e l s ,  
we further studied whether this difference is mecha-
nistically due to cellular location and D1 phosphory-
lation at Thr286 after NPCD treatment for 48 hours. In 
MCF7 cells, NPCD significantly decreased the Thr286 
phosphorylation  in  both  nuclear  and  cytoplasmic 
f r a c t i o n s   a t   h i g h   d o s e   ( 8   µ M )   (fig  6A).  This  result 
s e e m s   t o   b e   d i s c r e p a n t   w i t h   t h e   o b s e r v a t i o n s   t h a t   t h e  
l e v e l   o f   t o t a l   D 1   p r o t e i n   i n   e i t h e r   t h e   n u c l e u s   o r   t h e  
cytoplasm  remains  unchanged  (fig  6A)  or  that  the 
t o t a l   D 1   p r o t e i n   w a s   s l i g h t l y   d e c r e a s e d   a t   t h e   s a m e  
time point as seen in figure 5, since decreased Thr286 
phosphorylation  should  be  associated  with  an  in-
c r e a s e   i n   D 1   l e v e l .   I n   t h e   h i g h   d o s e   g r o u p   o f   M C F 7  
cells, CDK4 protein was decreased in both cytoplas-
mic and nuclear fractions (fig 6A). Cytoplasmic cyclin 
E in NPCD-treated MCF7 cells was decreased   i n   b o t h  
low- and high-dose groups while nuclear cyclin E did 
not show any obvious change (fig 6A). CDK2 in either 
the n u c l e u s   o r   t h e   c y t o p l a s m   d i d   n o t   s h o w   any con-
sistent change in NPCD-treated MCF7 cells.  
I n   M B 2 3 1   c e l l s ,   t h e   l e v e l s   o f   D 1   a n d   C D K 4   p r o-
tei n s   i n   e i t h e r   t h e   n u c l e u s   o r   t h e   c y t o p l a s m   d i d   n o t  
show  a  consistent  change.  However,  Thr286  phos-
phorylation was significantly decreased in the nuclear 
fraction by 8µM NPCD. Nuclear cyclin E seemed to be 
slightly decreased by NPCD while cytoplasmic cyclin 
E   w a s   n o t   o b v i o u s l y   a f f e c t e d   ( f i g   6 A ) .   C D K 2   d i d   n o t  
show significant change in either fraction. 
NPCD was designed to inhibit CDK4 activity by 
intervening  in  the  ATP  binding,  not  D1  binding 
[30,31].  Results  from  co-immunoprecipitation  assay 
s h o w e d   t h a t   N P C D   d i d   n o t   o b v i o u s l y   c h a n g e   t h e  
abundance of D1-C D K 4   c o m p l e x   i n   M C F 7 ,   M B 2 3 1   o r  
MCF15 cells. A decreased D1 level was detected by 
the  D1  immunoprecipitation  and  a  corresponding 
decrease in D1-associated CDK4 protein (fig 6B) was 
also detected in these cells, especially in MCF15 cells, 
w h i c h   a r e   l i k e l y   d u e   t o   t h e   d e c r e a s e   i n   t o t a l   D 1   p r o-
tein  as  shown  in  fig  5.  These  results  confirm  that 
NPCD  indeed  does  not  act  via  intervening  in  the 
D1-CDK4 binding.  
 
Changes in mRNA levels of G1 phase regulators 
upon NPCD treatment 
B e c a u s e   D 1 ,   C D K 4 ,   C D K 2 ,   c y c l i n   E ,   p 2 1 c i p 1   a n d  
p27kip1 showed changes  at  the protein levels upon 
N P C D   t r e a t m e n t ,   w e   p e r f o r m e d   R T -P C R   t o   d e t e r m i n e  
their  mRNA  levels  in  the  cells  treated  with  a  low 
(4μM) or a high (8μM) concentration o f   N P C D   f o r   7 2  
hours. In the low dose group, the D1 mRNA level was 
i n d u c e d   i n   M C F 7 ,   M B 2 3 1   a n d   M C F 1 5   c e l l s ,   c o m p a r e d  
with the non-treated counterparts (fig 7). However, in 
t h e   h i g h   d o s e   g r o u p   t h e   i n c r e a s e   i n   D 1   l e v e l   c o n t i n u e d  
i n   M B 2 3 1   c e l l s   b u t   i t   w a s   s l i ghtly leveled off in MCF7 
a n d   M C F 1 5   c e l l s   ( f i g   7 ) .   C D K 4   m R N A   l e v e l   w a s   i n-
d u c e d   b y   N P C D   i n   a l l   t h r e e   c e l l   l i n e s   i n   a   w a y   s i m i l a r  
t o   t h a t   o f   D 1   ( f i g   7 ) .   T h e   m R N A   l e v e l s   o f   c y c l i n   E   a n d  
C D K 2   w e r e   i n d u c e d   b y   N P C D   i n   M C F 7   a n d   M B 2 3 1  
c e l l s   b u t   n o t   i n   M C F 1 5   c e l l s   (fig 7). P21cip1 was in-
d u c e d   i n   M C F 7   c e l l s ,   a n d   t h e   i n d u c t i o n   w a s   e v e n  
higher at the high dose group. P21cip1 was also in-
d u c e d   i n   M B 2 3 1   a n d   M C F 1 5   c e l l s ,   b u t   t h e   i n d u c t i o n  
o c c u r r e d   o n l y   a t   t h e   l o w   d o s e   g r o u p .   P 2 7 k i p 1   w a s  
induced by both low and high doses of   N P C D   i n   b o t h  
M C F 7   a n d   M B 2 3 1   c e l l s ,   b u t   i n   M C F 1 5   c e l l s   t h e   i n d u c-
tion occurred only in the low dose group. 
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Fig 5: Western blot assay detects protein levels of cyclin D1 (D1), CDK4, CDK6, p27kip1, p21cip1, CDK2 and cyclin E in 
M C F 7 ,   M B 2 3 1   a n d   M C F 1 5   c e l l s   4 8   o r   7 2   h o u r s   a f t e r   t r e a t e d   treatment w i t h   4   o r   8   µ M   N P C D ,   c o m p a r e d   w i t h   t h e   u n t r e a t e d  
(0 µM) counterparts. β-actin is included as loading control. 
 
 
 
Fig 6: Location of, and complex formation b e t w e e n ,   c y c l i n   D 1   ( D 1 )   a n d   C D K 4 .   A): Western blot assay detects protein 
l e v e l s   o f   C D K 4 ,   t o t a l   D 1 ,   T h r 2 8 6   p h o s p h o r y l a t e d   D 1 ,   C D K 2   a n d   c y c l i n   E   i n   t h e   n u c l e a r   o r   c y t o p l a s m i c   f r a c t i o n   o f   M C F 7   o r  
MB231 cells 48 hours after treatment w i t h   4   o r   8   µ M   N P C D ,   w i t h   t h e   n o n -treated (0) cells as control. The Rb protein 
[86,87] and β-actin are included as the loading control for the nuclear and the cytoplasmic proteins, respectively. B): 
Co-immunoprecipitation assay detects the D1-C D K 4   c o m p l e x .   T o t a l   c e l l   l y s a t e s   w e r e   p r e p a r e d   f r o m   M C F 7 ,   M B 2 3 1   a n d  
MCF15 cells 48 or 72 hours after treatment with 4 or 8 µM NPCD. The protein lysates were first immunoprecipitated with 
D1 antibody, and the D1 immunoprecipitates were then fractioned in polyacrilamide gel and subjected to a western blot 
a s s a y   f o r   d e t e c t i o n   o f   D 1   o r   C D K 4   a s   i n d i c a t e d .   T h e   C D K 4   d etected in the D1 immunoprecipitates is considered to be 
associated with D1. Journal of Cancer 2011, 2 
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F i g   7 :   R T -PCR detection of mRNA levels of different genes in MCF7, MB231 and MCF15 cells 72 hours after treatment with 
4   o r   8   µ M   N P C D   o r   w i t h o u t   t h e   t r e a t m e n t .   N o t e   t h a t   t h e   β-actin included as the loading control also shows a slight dif-
f e r e n c e   i n   s o m e   o f   t h e   s a m p l e s ,   w h i c h   s h o u l d   b e   t a k e n   i n t o   a c c o u n t   w h e n   a   c h a n g e   i n   t h e   e x p r e s s i o n   o f   the desired gene is 
evaluated. 
 
Discussion 
Many  oncoproteins  and  growth  factors  utilize 
D 1   a s   a   c o m m o n   d o w n s t r e a m   e f f e c t o r .  In other words, 
D1 sensitizes the cells to various extracellular mito-
genic stimuli, such as estrogen and estrogen receptors 
in the case of breast cancer cells. Much of the D1’s role 
in  cell  cycle  progression  is  exerted  via  binding  to 
C D K 4   o r   C D K 6   t o   f o r m   a   h o l o e n z y m e ,   w h i c h   p h o s-
p h o r y l a t e s   t h e   p R b   p r o t e i n   t o   d r i v e   c e l l   p r o l i f e r a t i o n .  
Therefore, inhibition of CDK4 or CDK6 is presumably 
a good strategy for cancer therapy because cancers are 
characterized  by  uncontrolled  proliferation  and  fre-
quently  by increased D1-CDK4 activities [58,59]. We 
use NPCD, a novel indolocarbazole-derived inhibitor 
o f   C D K 4   a n d   C D K 6 ,   t o   t e s t   t his therapeutic principle 
and explore the pathways downstream of the CDK4 
inhibition. T h i s   t e s t   i s   n e e d e d   b e c a u s e   P D 0 3 3 2 9 9 1   i s   s o  
f a r   t h e   o n l y   C D K 4 / 6   i n h i b i t o r   t h a t   h a s   e n t e r e d   i n t o  
clinical trials for its chemotherapeutic potential. Our 
results show that NPCD, which has not been studied 
for its effect in cells, can indeed arrest breast cancer 
cell lines at G1 phase and cause cell death with IC50 
around  3-8   µ M   w h e n   i t   i s   a d m i n i s t e r e d   as a single, 
one-time, dose. A l t h o u g h   a   s t r o n g e r   p o t e n c y   i s   c o n-
ceivable  if  multiple  administrations  were  given  to 
maintain  the  NPCD  level  otherwise  metabolically 
decreased, the IC50 at 3-8 µM for cellular effects is still 
much higher than the reported IC50 for the in vitro 
inhibition of the CDK4 (45-7 5   n M )   o r   C D K 2   ( 2 7 0   n M )  
enzymatic activity [30,31,35]. There are several possi-
b l e   r e a s o n s   f o r   t h i s   d i s c r e p a n c y :   1 )   L i v e   c e l l s   m a y  
c o n t i n u e   p r o d u c i n g   C D K   p r o t e i n s   o n c e   t h e   e x i s t i n g  
C D K s   a r e   i n a c t i v a t e d   b y   N P C D ,   d u e   t o   a   c o n c e i v a b l e  
negative feedback mechanism. 2) Live cells have other 
N P C D   t a r g e t s   t h a t   a l s o   c o n s u m e   N P C D .   A t   l e a s t ,  
C D K 4 ,   C D K 6   a n d   C D K 2   w i l l   s i m u l t a n e o u s l y   c o n s u m e  
N P C D ,   t h u s   r a i s i n g   t h e   I C 5 0   f o r   t h e   c e l l u l a r   e f f e c t s .   3 )  
A certain portion  o f   N P C D   m a y   n o t   b e   i n t e r n a l i z e d  
into the cells while some other NPCD molecules may 
be metabolized. 4) The IC50 for growth inhibition and 
c e l l   d e a t h   s h o u l d   b e   m u c h   h i g h e r   t h a n   t h e   I C 5 0   f o r  
enzymatic  activity  of  CDK  proteins,  because  the  re-
maining activities of CDK4, CDK6 and CDK2 may be 
sufficient  to  maintain  cell  proliferation  or  viability. 
Besides these explanations, however, the much higher 
I C 5 0   m a y   r e f l e c t   t h a t   N P C D   h a s   o t h e r   c e l l u l a r   t a r g e t s  
that are accountable for the observed growth inhibi-
tion and cell death, since many chemical drugs have 
d i v e r s e   t a r g e t s   a n d   e f f e c t s .   P r o b a b ly,  p27kip1  and 
p21cip1  are  among  these  non-CDK  targets,  as  dis-Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
47 
cussed below. These issues deserve further explora-
tions. 
 A   w o n d e r f u l   s u r p r i s e   g i v e n   b y   o u r   r e s u l t s   i s   t h e  
long-lasting growth inhibition of breast cancer cells, 
especially  MCF7  cells,  because  clonogenic  survival 
assay shows that while there are many cells that sur-
vived the NPCD treatment they cannot propagate as 
fast  as  non-treated controls to form sizable colonies 
even 10-15 days after the cessation of the treatment. 
Another  reported  long-lasting  CDK  inhibitor  is 
R-roscovitine (CYC202), which has a relatively spe-
cific inhibitory activity towards cyclin E-CDK2  and 
shows a long-l a s t i n g   a r r e s t   o f   p o l y c y s t i c   k i d n e y   d i s-
ease  in  animals  [60].  Whether  such  long-lasting 
g r o w t h   i n h i b i t i o n   i s   a   t r a i t   o f   G 1   p h a s e   C D K   i n h i b i t o r s  
and what is t h e   u n d e r l y i n g   m e c h a n i s m   r e m a i n   t o   b e  
further studied.  
A   b a s i c   f i n d i n g   o f   t h e   p r e s e n t   s t u d y   i s   t h a t  
NPCD has relatively similar efficacy on five human 
breast cancer cell lines, although these cells have dif-
ferent properties of tumor biology  pertaini n g   t o   s u c h  
as  p53,  estrogen  receptor,  metastatic  statuses,  etc. 
Actually,  even  non-malignant  MCF10A  cells  show 
only  a  small  difference  in  the  sensitivity.  Use  of 
non-transformed epithelial cell lines such as MCF10A 
a s   “ n o r m a l   c o n t r o l ”   i n   t h e   s t u d i e s   o f   c h emoresponse 
h a s   d i s a d v a n t a g e s .   O n e   t h a t   i s   o f t e n   n e g l e c t e d   i s   t h a t  
these  cell  lines  require  different  culture  conditions, 
such as glucocorticoid and other supplements (hEGF, 
insulin,  cholera  toxin,  etc),  for  an  optimal  growth. 
When these cells are cultured in a routine condition 
used for most epithelial-derived cancer cell lines, they 
a r e   m o r e   f r a g i l e   t h a n   c a n c e r   c e l l s   a n d   t h u s   e a s i e r   t o  
d i e .   A c t u a l l y ,   M C F 1 0 A   i s   n o t   m u c h   l e s s   s e n s i t i v e   t o  
some other chemotherapeutical agents either (unpub-
lished data). If all cells are cultured in a special me-
d i u m   f o r   M C F 1 0 A ,   t h e   d a t a   m a y   n o t   b e   u s e d   b r o a d l y  
since most cancer cells are not routinely cultured with 
many  supplements  and  glucocorticoid  that  may  in-
fluence the effects of the agent to be tested. For this 
reason, we culture all cells in routine DMEM medium 
and serum without additional supplements that may 
affect  data  interpretation,  although  it  is  not  optimal 
for MCF10A. 
The effect of NPCD is associated with decreased 
phosphorylation of the Rb protein at Ser780, Ser807 
and  ser811  as  expected.  Of  the  cell  lines  studied, 
MB231 is so-called triple-negative, i.e. absence of es-
trogen receptor, progesterone receptor and Her-2 re-
ceptor expression. Triple-negativity is a special cate-
gory of breast cancer that is notorious for its refracto-
riness  to  various  chemotherapies  and  for  its  worse 
prognosis  [61],  but  MB231  cells  are  still  relatively 
sensitive to NPCD. However, MB231 cells express Rb 
protein whereas many other triple-negative  cells  are 
basal-cell  like  and  lack  Rb  expression  [62].  Several 
studies have  shown that  Rb-proficient  cells  of breast 
cancer [47] and other cancer types [63,64] are  more 
sensitive  to  PD0332991  than  the  Rb-deficient  coun-
terparts. Probably, Rb-deficient breast cancer cells are 
r e l a t i v e l y   r e s i s t a n t   t o   N P C D   a s   w e l l , which deserves 
exploration  later. H o w e v e r ,   i n   t h e   R b -proficient cell 
lines, the protein level of Rb usually varies little and is 
thus used by some investigators as loading control in 
western  blot  assay  [54,55].   A s   e x p e c t e d ,   w e   d i d   n o t  
detect a significant difference in the Rb level among 
the cell lines studied, nor a correlation between the 
sensitivity to NPCD and the Rb protein level. We in-
t e n d   t o   c o n s i d e r   t h a t   a   c o m p l e t e   l a c k   o f   R b   m a y   a f f e c t  
t h e   r e s p o n s e   o f   c e l l s   t o   C D K 4   i n h i b i t o r s   b u t   i n   t h e  
Rb-proficient cells its protein level may not signifi-
cantly influence the response. 
Finn  et  al  reported  recently  that  PD0332991  is 
more effective on high D1 breast cancer cells [47], and 
Dai et al also report that D1 overexpression increases 
t h e   s u s c e p t i b i l i t y   o f   h u m a n   U 2 6 6   m y e l o m a   c e l l s   t o  
CDK inhibitors [65]. We found that the two relatively 
less sensitive cell lines, T47D and GI101Ap, express a 
relatively lower level of D1 and/or CDK4 compared 
with the other three more-sensitive cell lines, which is 
in lin e   w i t h   t h e   o b s e r v a t i o n s   o f   F i n n   e t   a l   [47] and Dai 
et  al  [65]  and  dovetails  with  the  assumption  that 
NPCD  has  its  effect  by  targeting  the  D1-CDK4  ho-
l o e n z y m e .   C o n s i d e r i n g   t h a t   D 1   m a y   i m p o s e   r e s i s t a n c e  
to  other  chemotherapeutic  agents  onto  pancreatic 
cancer and probably also onto  other  cancers,  as  re-
viewed by us [1], CDK4 inhibitors may be prescribed 
especially to those cancers that show high D1-CDK4 
activities  or  D1-CDK4  imposed  chemotherapeutic 
resistance. 
T h e r e   a r e   v e r y   f e w   s t u d i e s   o n   h o w   C D K 4 / 6   i n-
hibitory  compounds  affect  the  expression  of  D1, 
CDK4 and other G1 regulatory genes, and PD0332991 
does not seem to have a   c o n s i s t e n t   e f f e c t   o n   D 1   p r o-
tein level [66]. We therefore put specific efforts on this 
i s s u e .   M C F 7   a n d   M C F 1 5   s e e m   t o   r e p r e s e n t   a   g r o u p   o f  
breast cancer cells that show decreases in both D1 and 
C D K 4   u p o n   t r e a t m e n t   w i t h   N P C D ,   w h e r e a s   M B 2 3 1  
may represent another type of breast cancer cells that 
shows induction of D1 with unchanged CDK4 levels. 
CDK6  is  expressed  at  relatively  low  level  in  these 
breast  cancer  cells  and  does  not  show  a  consistent 
p a t t e r n   o f   c h a n g e s   i n   r e s p o n s e   t o   N P C D   t r e a t m e n t .  
Although D1 is considered an oncogene that drives 
cell proliferation, it can also cause apoptosis in certain 
undefined situations [1]. Questions that remain to be 
a n s w e r e d   i n c l u d e   h o w   D 1   c h o o s e s   t o   d r i v e   p r o l i f e r a-
t i o n   o r   c e l l   d e a t h   a n d   w h e t h e r   t h i s   d e c i s i o n   i s   m a d e  Journal of Cancer 2011, 2 
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under influence of CDK4/6 status. M o r e o v e r ,   i t   i s   a l s o  
unclear whether CDK4 alone has dual-functions, i.e. 
can  cause  apoptosis  as  well.  We  infer  that  D1,  by 
b i n d i n g   t o   C D K 4 / 6 ,   m a y   p r o t e c t   b r e a s t   c a n c e r   c e l l s  
from drug-induced  cell death [1]. However, once the 
D1-CDK4  activity  is  inh i b i t e d   b y   N P C D   a n d   c o n-
ceivably  also  PD0332991  or  other  CDK4  inhibitory 
c o m p o u n d s ,   t h e   D 1   a n d   C D K 4   p r o t e i n s   b e c o m e  
“useless” and are thus degraded via unknown me-
chanisms. Without D1-CDK4  sustaining their surviv-
a l ,   t h e   c e l l s   t h u s   u n d e r g o   g r o w t h   a r r e s t   a n d   d emise. 
This may be the situation occurring in the cell type 
represented  by  MCF7  and  MCF15  cells.  In  the  cell 
t y p e   p r e s e n t e d   b y   M B 2 3 1 ,   i n   w h i c h   N P C D   c a n n o t  
decrease  or  even  induces  D1  and  CDK4,  the  abun-
dant,  but  kinase-dead,  D1-CDK4  holoenzyme  may 
directly promote cell death since it is no longer able to 
p h o s p h o r y l a t e   t h e   R b   t o   d r i v e   c e l l   c y c l e   p r o g r e s s i o n .  
This intriguing hypothesis needs to be tested later. 
P h o s p h o r y l a t i o n   o f   D 1   p r o t e i n   a t   T h r 2 8 6   b y  
GSK-3β is supposed to trigger proteasomal degrada-
tion  of  D1  [2].  The  abundance  of 
Thr286-phosphorylated D1 is unexpectedly decreased 
by  NPCD  in both  the cytoplasmic and nuclear frac-
t i o n s   o f   M C F 7   c e l l s ,   w h i c h   o p p o s e s   o u r   o r i g i n a l   e x-
pectation that the Thr286 phosphorylation should be 
i n c r e a s e d ,   n o t   d e c r e a s e d ,   i n   M C F 7   c e l l s   a s   a   m e c h a n-
i s m   u n d e r l y i n g   t h e   d e c r e a s e d   l e v e l   o f   D 1   p r o t e i n   7 2  
h o u r s   p o s t   N P C D   t r e a t m e n t   a s   s e e n   i n   f i g u r e   5 .  
Therefore, phosphorylation at Thr286 is insufficient to 
degrade  D1  protein  in  MCF7  and  probably  also 
MCF15 cells. Aspirin has been shown to rapidly de-
grade  D1  protein  by  activation  of  p38  mito-
gen-activated  protein  kinase  (MAPK),  resulting  in 
apoptosis  of  the  cells  [50].  There  are  some  other 
compounds  with  therapeutic potential  that  can  also 
cause  D1  protein  degradation,  such  as  STG28  [67], 
silibinin [68], fucoxanthin [69] and metformin [70,71]. 
O f   t h e s e   c o m p o u n d s ,   S T G 2 8   i s   k n o w n   t o   d e g r a d e   D 1  
protein via a novel mechanism independent of Thr286 
phosphorylation  [67],  whereas  it  is  unclear  whether 
degradation of D1   b y   t h e   o t h e r   c o m p o u n d s   r e q u i r e s  
phosphorylation at Thr286. Therefore, the unexpected 
finding  that  a  pronounced  decrease  in 
Thr286-phosphorylation  is  not  companied  with  an 
increase in D1 protein level in MCF7 cells is of interest 
a n d   d e s e r v e s   f u r t h e r   s t u d ies for the underlying me-
chanism. 
C y c l i n   E   a n d   C D K 2   p r o t e i n   l e v e l s   a l s o   s h o w   o b-
v i o u s   c h a n g e s   i n   r e s p o n s e   t o   N P C D   t r e a t m e n t   i n   s o m e  
cell  lines.  However,  in  most  occasions  the  changes 
s h o w   a   r e c i p r o c a l   p a t t e r n ,   i . e .   a   d e c r e a s e   i n   c y c l i n   E   i s  
companied by an i n c r e a s e   i n   C D K 2   a n d   v i c e   v e r s a .   I t  
is possible that an NPCD-induced decrease in cyclin E 
o r   C D K 2   m a y   t r i g g e r   a   n e g a t i v e   f e e d b a c k   m e c h a n i s m  
t o   i n c r e a s e   t h e   l e v e l   o f   i t s   p a r t n e r .   I t   i s   c o n c e i v a b l e  
that such a reciprocal change may help stabilizing the 
cyclin E-C D K 2   a c t i v i t y .   T h e r e f o r e ,   t h e   c y c l i n   E -CDK2 
holoenzyme may not be a primary target of NPCD for 
its chemotherapeutic effects. 
Another unexpected finding in our study is the 
decrease  in  the  p27kip1  protein  in  all  three 
NPCD-treated  cell  lines,  i.e.  MCF7,  MB231  and 
MCF15 cells. P21cip1 protein level is also decreased in 
M C F 7   a n d   M C F 1 5   c e l l s ,   a l t h o u g h   n o t   i n   M B 2 3 1   c e l l s .  
These  results  are  unexpected  because  most  chemo-
therapeutic  agents  induce,  not  decrease,  these  CDK 
inhibitory proteins. For instance, anticancer activities 
of  R-roscovitine  (a  CDK2  inhibitor)  [72],  inositol 
hexphosphate [73], Silibinin [68] and ZD1839 [74] are 
associated  with  increased  p27kip1  and/or  p21cip1. 
O n   t h e   o t h e r   h a n d ,   l o s t   e x p r e s s i o n   o f   t h e s e   C D K   i n h i-
b i t o r y   g e n e s ,   e s p e c i a l l y   t h e   p 2 7 k i p 1 ,   i s   s u g g e s t e d   a s   a  
c o m m o n   r e a s o n   f o r   t h e   r e s i s t a n c e   o f   c a n c e r   c e l l s   t o  
certain  chemotherapeutic  agents  [75,76].  Therefore, 
NPCD may represent a new category of chemothera-
peutic compounds that compensate for the weakness 
o f   t h o s e   a g e n t s   t h a t   r e q u i r e   p 2 7 c i p 1   o r   p 2 1 c i p 1   t o   e l i c i t  
their therapeutic effects. However, whether and how 
decreases of these CDK inhibitory proteins contribute 
to  NPCD-induced  cell  death  of  cancer  cells  are  un-
known. Probably p27kip1 and p21cip1 are also cellu-
l a r   t a r g e t s   o f   N P C D ,   b e s i d e s   G 1   p h a s e   C D K s ,   a s   a  
reason for a much higher IC50 for the cellular effects 
as  discussed  above.  Increased  abundance  of  the 
D1-C D K 4   c o m p l e x   i s   k n o w n   t o   t r a p   m o r e   p 2 7 k i p 1  
and/or p21cip1 in the complex, indirectly preventing 
cyclin E-CDK2 holoenzyme from inhibition by these 
CDK inhibitors. As the result, cells are enhanced  to 
complete the G1-S phase transit and accelerate the S 
phase. Our results raise an intriguing question as to 
whether decreases in p27kip1 and/or p21cip1 per se 
can cause apoptosis when D1-CDK4  holoenzyme  is 
either decreased or inactivated. This question is valid 
for at least two reasons: 1) p27kip1 or p21cip1 is ac-
tually required for assembling the cyclin-CDK  com-
plex and  bringing  the  complex  into  the  nucleus  be-
c a u s e   n e i t h e r   D 1   n o r   C D K 4   h a s   a   c a n o n i c a l   n u c l e a r  
localization sequence whereas p27kip1 or p21cip1 has 
[77,78].  2 )   T h e s e   p r o t e i n s   c a n   a l s o   f u n c t i o n   a s   o n c o-
genes to promote tumor formation or to render cancer 
cells  resistant  to  anticancer  therapies  under  certain 
situations  [79-82].  Whether  PD0332991  and  other 
CDK4/6  inhibitory  compounds  also  decrease  the 
protein levels of p21cip1 and p27kip1 is another in-
teresting question waiting for an answer. 
T h e   m R N A   l e v e l s   o f   p 2 7 k i p 1 ,   p 2 1 c i p 1 ,   D 1 ,  
C D K 4 ,   C D K 2   a n d   c y c l i n   E   a r e   i n d u c e d   b y   N P C D   a t  Journal of Cancer 2011, 2 
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concentrations  around  the  IC50  in  different  breast 
cancer cell lines,   w h i c h   i s   a   s u r p r i s e   t o   u s   b e c a u s e   w e  
expected that NPCD might also  have  certain  inhibi-
t o r y   e f f e c t s   o n   C D K 7   a n d   C D K 9 ,   j u s t   l i k e   m a n y   o t h e r  
CDK  inhibitory  compounds,  although  this  has  not 
really been studied. CDK7 and CDK9 are required for 
transcriptional elongation of mRNAs, and thus their 
inhibition results in decrease in the mRNA levels of 
m o s t ,   i f   n o t   a l l ,   g e n e s   [83]. Therefore, the increases in 
the mRNA levels of many genes observed herein in-
directly suggest that NPCD may not be very potent in 
i n h i b i t i o n   o f   C D K 7   a n d   C D K 9 .   H o w e v e r ,   a   w e a k e r  
inhibition may still occur, at least in certain cells, since 
N P C D   a t   8   µ M   s e e m s   t o   d e c r e a s e   t h e   l e v e l s   o f   a l l   t h e  
g e n e s   i n   M C F 1 5   c e l l s   ( f i g   7 ) .   F u r t h e r   s t u d y   o n   t h e   e n-
zymatic activity is required to clarify this issue. 
In summary, we show for the first time that the 
CDK4  inhibitory  compound  NPCD  can  cause 
long-l a s t i n g   g r o w t h   a r r e s t   a n d   c e l l   d e a t h   o f   b r e a s t  
c a n c e r   c e l l   l i n e s   a t   a n   I C 5 0   o f   3 -8 µM. An expected 
decrease  in  the  Rb  phosphoryla t i o n   b y   D 1 -CDK4/6 
and an unexpected decrease in p27kip1 protein level 
may be part of the underlying mechanism, although 
the  D1  and  CDK4  protein  levels  show  different 
changes  among  different  cell  lines  treated  with 
NPCD.  
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